Advancing Next-Generation Probiotics: Faecalibacterium longum based Microbiome Therapeutic Research Service
The landscape of modern medicine is shifting from broad-spectrum interventions toward the precision of the human microbiome. Among the diverse array of commensal bacteria inhabiting the human gut, the genus Faecalibacterium has emerged as a cornerstone of intestinal health. While Faecalibacterium prausnitzii has long been the focus of clinical curiosity, recent genomic and phenotypic characterization has spotlighted "Faecalibacterium longum" as a distinct and potent candidate for Live Biotherapeutic Products (LBPs).
As a leading Contract Research Organization (CRO) specializing in preclinical microbiome research, we provide the infrastructure, expertise, and specialized models required to transition F. longum from a laboratory isolate to a validated therapeutic lead. Our comprehensive "Faecalibacterium longum-based Microbiome Therapeutic Research Service" is designed to support biotech innovators and pharmaceutical researchers in navigating the complex biological and regulatory hurdles of live biotherapeutics.
Overview: The Significance of Faecalibacterium longum
The human gut microbiota is a complex ecosystem where specific "keystone species" maintain immunological and metabolic homeostasis. Faecalibacterium longum, a Gram-positive, anaerobic, non-spore-forming bacterium, is one such species. Originally distinguished from the broader F. prausnitzii cluster through advanced phylogenomic analysis, F. longum has demonstrated unique metabolic profiles that make it particularly attractive for therapeutic intervention. Unlike many common probiotics, F. longum is an obligate anaerobe, meaning it is extremely sensitive to oxygen. This characteristic, while challenging for manufacturing, is exactly what makes it a highly effective inhabitant of the deep mucosal layers of the human colon. It is a primary producer of butyrate, a short-chain fatty acid (SCFA) that serves as the main energy source for colonocytes and plays a critical role in maintaining the integrity of the intestinal barrier.
Traditional probiotics (like Lactobacillus or Bifidobacterium) have dominated the market for decades. However, F. longum represents the "Next-Generation Probiotic" (NGP) movement-bacteria that are naturally abundant in the healthy human gut but depleted in various disease states. By leveraging our research services, partners can explore how restoring F. longum levels can reverse dysbiosis and treat chronic inflammatory conditions.
Our Preclinical Research Services
Navigating the preclinical phase of an LBP requires a blend of microbiology, molecular biology, and complex animal modeling. Our CRO offers an end-to-end suite of services specifically tailored for Faecalibacterium longum.
We provide high-resolution isolation services from human donor samples. This includes phenotypic characterization (morphology, growth kinetics, and metabolic profiling) and genotypic validation using Whole Genome Sequencing (WGS). We also offer secure Master Cell Bank (MCB) and Working Cell Bank (WCB) creation to ensure the stability and purity of your research strains.
F. longum is extremely sensitive to oxygen (extremely oxygen-sensitive, or EOS). Our facilities are equipped with state-of-the-art anaerobic chambers and bioreactors. We optimize fermentation conditions, pH, temperature, and media composition, to maximize biomass yield and metabolite production, ensuring your scale-up process is viable.
We maintain a suite of specialized animal models to test the therapeutic impact of F. longum:
DSS-Induced Colitis Models: To evaluate anti-inflammatory and mucosal repair capabilities.
High-Fat Diet (HFD) Models: To study metabolic and weight-management effects.
Germ-Free and Gnotobiotic Models: To study the strain in a controlled microbial environment, allowing for precise determination of its ecological impact.
Safety is the cornerstone of Live Biotherapeutics. Our services include antibiotic susceptibility testing (AST) to ensure the strain does not carry transmissible resistance genes, as well as acute and sub-chronic oral toxicity studies in accordance with regulatory guidelines.
Premium Products for Research and Development
To support your internal R&D efforts, we offer a range of standardized products derived from or related to Faecalibacterium longum.
Faecalibacterium prausnitzii is Gram-positive, mesophilic, rod-shaped, anaerobic and is one of the most abundant and important commensal bacteria of the human gut microbiota.
Faecalibacterium prausnitzii is Gram-positive, mesophilic, rod-shaped, anaerobic and is one of the most abundant and important commensal bacteria of the human gut microbiota.
Faecalibacterium prausnitzii is Gram-positive, mesophilic, rod-shaped, anaerobic and is one of the most abundant and important commensal bacteria of the human gut microbiota.
Faecalibacterium prausnitzii DNA Standard product can be used for quantitative research and analysis, assay development, verification, and validation, and laboratory quality control.
This product contains high-quality, intact genomic DNA isolated from Faecalibacterium prausnitzii Genomic DNA. It is a purified and ready-to-use DNA sample, ideal for a wide range of molecular biology applications, including PCR, qPCR, and Next-Generation Sequencing.
Research Application of F. longum in Disease Treatment
Current research indicates that F. longum is not merely a bystander in the gut; it is an active participant in immune modulation. Its therapeutic potential is being explored across several high-impact disease areas.
The most prominent application of F. longum research is in Crohn's Disease and Ulcerative Colitis. Patients with active IBD consistently show a significant reduction in Faecalibacterium abundance. Research suggests that F. longum secretes anti-inflammatory peptides (such as MAM - Microbial Anti-inflammatory Molecule) that inhibit the NF-κB pathway, thereby reducing the production of pro-inflammatory cytokines like IL-12 and TNF-α.
Emerging studies have linked F. longum to improved metabolic health. By strengthening the gut barrier-often referred to as fixing "leaky gut"-this strain prevents the translocation of lipopolysaccharides (LPS) into the bloodstream. This reduction in metabolic endotoxemia can improve insulin sensitivity and assist in the management of Type 2 Diabetes and non-alcoholic fatty liver disease (NAFLD).
3. The Gut-Brain Axis and Mental Health
The "Psychobiotic" potential of F. longum is a burgeoning field. By modulating the systemic inflammatory response and producing metabolites that interact with the vagus nerve, research is investigating its role in alleviating symptoms of major depressive disorder and anxiety. Preclinical models have shown that F. longum supplementation can influence hippocampal neurogenesis and stress-response markers.
4. Immuno-Oncology
Perhaps the most cutting-edge application involves the enhancement of cancer immunotherapy. There is a growing body of evidence that a microbiome rich in Faecalibacterium species correlates with better patient responses to Anti-PD-1/PD-L1 checkpoint inhibitors. Our research services help developers understand how F. longum primes the systemic immune system to better recognize and attack tumors.
Why Choose Us? Our Strategic Advantages
Choosing the right CRO partner is vital for the success of your microbiome program. Our company stands out due to our deep specialization and commitment to quality.
Deep Expertise in Anaerobic Microbiology
Many CROs struggle with the "unculturable" nature of the gut microbiome. We have mastered the art of culturing EOS bacteria, ensuring high viability and consistent results.
Integrated Multi-Omics Platform
We don't just provide raw data; we provide insight. By integrating metagenomics, transcriptomics, and metabolomics, we offer a holistic view of how F. longum interacts with the host.
State-of-the-Art Infrastructure
From anaerobic workstations to high-throughput sequencers and GSF (Germ-Free) animal facilities, we possess the infrastructure required for top-tier preclinical research.
Regulatory Alignment
Our protocols are designed with future IND (Investigational New Drug) applications in mind. We provide the documentation and data integrity required by global regulatory bodies.
Tailored Solutions
We understand that every research project is unique. Our team of PhD-level scientists works closely with you to design custom study protocols that address your specific therapeutic targets.
The potential of Faecalibacterium longum to revolutionize the treatment of inflammatory, metabolic, and neurological diseases is no longer a matter of "if," but "when." As the scientific community continues to move away from broad-spectrum probiotics toward precision microbiome medicine, the demand for rigorous, strain-specific research has never been higher. By focusing on the unique metabolic output and immunomodulatory properties of F. longum, researchers can unlock new pathways for healing that work in harmony with the body's natural ecology.
Our organization is dedicated to being the engine behind these discoveries. We provide the tools, the expertise, and the biological insights necessary to navigate the complexities of the gut environment. Whether you are a biotech startup or an established pharmaceutical company, our Faecalibacterium longum-based research services are designed to accelerate your timeline and ensure the highest standards of scientific integrity.
Why is Faecalibacterium longum so difficult to work with?
F. longum is an extremely oxygen-sensitive (EOS) bacterium. Even brief exposure to ambient air can lead to a total loss of viability. Working with this strain requires specialized anaerobic chambers, deoxygenated media, and rapid handling techniques that we have perfected over years of experience.
Is F. longum the same as F. prausnitzii?
While they belong to the same genus and share many beneficial traits (like butyrate production), they are distinct species with different genetic profiles and metabolic niches. Researching F. longum specifically allows for more targeted therapeutic strategies and potentially better colonization in certain patient populations.
Can you help with the scale-up of F. longum for clinical trials?
Yes. Our process development team specializes in moving from small-scale laboratory culture to large-scale bioreactor fermentation, optimizing stabilization methods like freeze-drying to ensure the final product is both potent and stable.
Do you offer assistance with regulatory filings?
While we are a preclinical CRO, the data packages we provide are specifically formatted to support the "Chemistry, Manufacturing, and Controls" (CMC) and "Nonclinical Safety" sections of regulatory filings.
Online Inquiry
For Research Use Only. Not intended for use in
food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
